141 related articles for article (PubMed ID: 16626793)
1. The impact of PET/CT in the management of recurrent ovarian cancer.
Simcock B; Neesham D; Quinn M; Drummond E; Milner A; Hicks RJ
Gynecol Oncol; 2006 Oct; 103(1):271-6. PubMed ID: 16626793
[TBL] [Abstract][Full Text] [Related]
2. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
3. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
4. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
6. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.
Bristow RE; del Carmen MG; Pannu HK; Cohade C; Zahurak ML; Fishman EK; Wahl RL; Montz FJ
Gynecol Oncol; 2003 Sep; 90(3):519-28. PubMed ID: 13678719
[TBL] [Abstract][Full Text] [Related]
7. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
Soussan M; Wartski M; Cherel P; Fourme E; Goupil A; Le Stanc E; Callet N; Alexandre J; Pecking AP; Alberini JL
Gynecol Oncol; 2008 Jan; 108(1):160-5. PubMed ID: 17961640
[TBL] [Abstract][Full Text] [Related]
8. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography in the management of documented or suspected recurrent ovarian cancer.
Chou HH; Chen CY; Liu FY; Lin G; Wang CC; Yang LY; Chen MY; Pan YB; Wu RC; Yen TC; Chang TC; Lai CH
J Formos Med Assoc; 2017 Nov; 116(11):869-879. PubMed ID: 28089190
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
13. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis.
Gu P; Pan LL; Wu SQ; Sun L; Huang G
Eur J Radiol; 2009 Jul; 71(1):164-74. PubMed ID: 18378417
[TBL] [Abstract][Full Text] [Related]
14. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.
Fulham MJ; Carter J; Baldey A; Hicks RJ; Ramshaw JE; Gibson M
Gynecol Oncol; 2009 Mar; 112(3):462-8. PubMed ID: 19150121
[TBL] [Abstract][Full Text] [Related]
15. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
[TBL] [Abstract][Full Text] [Related]
16. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
[TBL] [Abstract][Full Text] [Related]
17. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
Makhija S; Howden N; Edwards R; Kelley J; Townsend DW; Meltzer CC
Gynecol Oncol; 2002 Apr; 85(1):53-8. PubMed ID: 11925120
[TBL] [Abstract][Full Text] [Related]
19. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
20. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]